Koselugo (selumetinib) for the Treatment of Neurofibromatosis Type 1 (NF1)

Image 1-Koselugo
Koselugo® (selumetinib) is the first FDA approved drug indicated for the treatment of neurofibromatosis type 1 (NFI). Credit: Astrazeneca.